Loading clinical trials...
Loading clinical trials...
A Phase 2, Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Viagenpumatucel-L (HS-110) in Combination With Low Dose (Metronomic) Cyclophosphamide Versus Chemotherapy Alone in Patients With Non-Small Cell Lung Adenocarcinoma After Failure of Two or Three Previous Treatment Regimens for Advanced Disease
Conditions
Interventions
Viagenpumatucel-L
Metronomic Cyclophosphamide
+1 more
Locations
16
United States
Highlands Oncology Group
Rogers, Arkansas, United States
University of California San Diego
La Jolla, California, United States
University of California at Los Angeles
Los Angeles, California, United States
University of California Davis
Sacramento, California, United States
Georgia Regents University
Augusta, Georgia, United States
University of Maryland Greenebaum Cancer Center
Baltimore, Maryland, United States
Start Date
July 1, 2014
Primary Completion Date
December 1, 2017
Completion Date
April 1, 2018
Last Updated
February 5, 2020
NCT05671510
NCT03340506
NCT07485114
NCT06066138
NCT05098132
NCT04977453
Lead Sponsor
Heat Biologics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions